Plasma cell leukemia (PCL) is an aggressive and rare plasma cell neoplasm defined by the presence of malignant clonal plasma cells circulating in the peripheral blood at levels exceeding 2×10¹/L or comprising 20% or more of the leukocyte differential count. PCL may arise de novo as primary plasma cell leukemia or develop as a late-stage transformation of multiple myeloma. Prevalence data are not certified in this packet. The condition is not inherited; it results from acquired somatic changes in plasma cells rather than germline genetic variants.

Clinical manifestations of plasma cell leukemia are not detailed in this packet's certified phenotype records. As an aggressive plasma cell malignancy involving the peripheral blood and bone marrow, the specific documented phenotypic features for this condition are not available in the current record.

Plasma cell leukemia arises from the acquired malignant transformation of clonal plasma cells. No germline causative genes are certified in this packet; no inheritance patterns apply. The molecular basis involves somatic alterations within the malignant plasma cell clone.

Diagnostic criteria are not detailed in this packet beyond the defining threshold: clonal plasma cells in the peripheral blood exceeding 2×10¹/L or comprising 20% or more of the leukocyte differential count. Further diagnostic methodology is not certified in this record.

No FDA-approved treatments specifically indicated for plasma cell leukemia are documented in this packet. The absence of approved therapies for this condition in the current record reflects both its rarity and the active clinical investigation landscape surrounding it. Supportive agents used in related plasma cell malignancies are not certified as approved for this specific indication in this record.

Certified population-level natural history or outcome data are not available in this packet. Prognosis data specific to plasma cell leukemia are not certified in this record.

Plasma cell leukemia is an area of active clinical investigation, with numerous trials registered on ClinicalTrials.gov. Trial records include studies examining CAR-T cell approaches, transplantation strategies, and novel drug combinations in the plasma cell leukemia setting. Active clinical trials for this condition are listed on ClinicalTrials.gov.